Cercano Management LLC Sells 444 Shares of Johnson & Johnson $JNJ

Cercano Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 18.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,925 shares of the company’s stock after selling 444 shares during the period. Cercano Management LLC’s holdings in Johnson & Johnson were worth $294,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.4%

Shares of NYSE:JNJ opened at $196.00 on Friday. The firm has a market cap of $472.22 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $197.18. The company’s fifty day simple moving average is $185.81 and its 200 day simple moving average is $170.04. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Finally, Bank of America boosted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.